ApconiX Welcomes Steve Snyder

ApconiX is delighted to welcome Steve Snyder to the team.  Steve joins the nonclinical study monitoring team and is based in Florida in the United States.

Having worked at Wyeth, Eli Lilly, McNeil Pharmaceutical and Charles River, Steve has a wealth of experience in preclinical toxicology as both an outsourcing customer and provider.  He is familiar with the management, staff and capabilities of the major CROs.

Steve graduated with a degree in biology from Bloomsburg University and a master’s degree in biology from Villanova University in Pennsylvania.  Early in his career he designed, conducted, and prepared reports for toxicology studies to support regulatory submissions.  Steve became a toxicology department head for Eli Lilly directing all scientific and regulatory activities and conducted key studies on several commercially successful drugs. At Charles River, he learned the inner workings of a CRO with responsibilities in marketing, business development, and project management.

Steve has written extensively about preclinical outsourcing in the trade publication, Contract Pharma.  Steve is a member of the American College of Toxicology and the Society of Toxicology.

“With over 40 years industry experience in toxicology operations, study management, and nonclinical outsourcing, I am looking forward to adding to and learning from the expertise of the ApconiX team,” added Steve.

Dr Richard Knight, Director and Co-Founder of ApconiX, commented, “We are delighted to be joined by someone of Steve’s reputation and experience.  With a growing number of clients in the US, Steve will strengthen the ability of the ApconiX team to support studies at North American CROs.”

By |2019-02-06T09:53:22+00:00February 6th, 2019|Nonclinical Study Monitoring, Careers|Comments Off on ApconiX Welcomes Steve Snyder

About the Author:

Dr Richard Knight PhD, ERT, is a Director and Co-founder of ApconiX, a preclinical toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts. Richard graduated from the University of Bradford in 1989 with a degree in Biomedical Sciences (Pharmacology) before gaining a PhD at the University of Leeds researching the role of adenosine receptors in renal function and toxicity. His research then included post-doctoral studies at University of California, Los Angeles (UCLA) into the effects of ischaemia/reperfusion injury on cardiac metabolism. Richard joined Zeneca Pharmaceuticals, Safety of Medicines Group in 1996 as a Study Director, and then Project Toxicologist across multiple therapy areas, from early discovery through to market. As Lead Toxicologist for Oncology, Richard was a member of both the Drug Safety and Metabolism, and Oncology Leadership teams with responsibility for safety across the AZ oncology portfolio. In this senior role he provided leadership and mentoring support to other project toxicologists. Richard has worked on many drug platforms over this time including small molecules, biologics, proteins and oligonucleotides and has been involved in bringing over 30 new candidate drugs into clinical trials and 5 to marketing approval.